The Big 3: China’s Export Surge, the Fight Over PNTR, Rising Biotech Race Reshape U.S. Strategy.

Описание: The United States is entering a new phase of economic competition with China—and the policy choices made now will shape the future of American industry, technology, and national security. This week’s episode of The Big 3 examines three major developments that highlight the growing urgency of a true “China reckoning” in U.S. trade policy.

First, CPA economists Mihir Torsekar and Andrew Rechenberg break down the newly released USTR 2026 Trade Policy Agenda and the president’s annual trade report. While the document acknowledges the scale of China’s export-driven model—including a staggering $1.2 trillion global trade surplus in 2025—it stops short of proposing the structural solutions needed to address the problem. China’s state-backed overcapacity continues to flood global markets with artificially cheap goods, driving down prices and undermining U.S. industries across sectors ranging from metals and plastics to vehicles and furniture. The report identifies the challenge—but meaningful policy action remains uncertain.

Second, the conversation turns to a new U.S. International Trade Commission investigation into revoking China’s Permanent Normal Trade Relations (PNTR) status. Granting PNTR helped cement China’s integration into the global trading system, but the results have been costly for American manufacturing. Studies estimate the United States lost millions of jobs as China’s state-directed export machine expanded. Moving China to higher “Column 2” tariff rates would represent a fundamental reset in U.S.–China trade relations and could restore a more level competitive playing field for American producers.

Finally, the episode explores China’s rapid advances in biotechnology, a sector where the United States has long held the global edge. China is now launching more clinical trials, expanding research capacity, and attracting billions in licensing deals from Western pharmaceutical companies. If current trends continue, the U.S. risks outsourcing not just manufacturing—but the next generation of medical innovation—to its primary geopolitical rival.

Taken together, these developments underscore a single reality: the era of complacency in U.S.–China economic policy is over.